Found 111 matching trials
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis PHASE2 This phase II trial studies how well radiation therapy given with standard ...
Show More Location
Grady Health System
Learn More & Join Trial
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer PHASE1 The main purpose of this research study is to learn whether the investigati...
Show More Location
Abramson Cancer Center of the University of Pennsylvania
Learn More & Join Trial
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer PHASE2 This phase II trial studies the side effects and how well palbociclib and l...
Show More Location
Anchorage Associates in Radiation Medicine
Learn More & Join Trial
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer PHASE1 This study adopts multicenter/randomized trial design. It plans to enroll p...
Show More Location
Multiple Locations
Learn More & Join Trial
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region N/A retrospective non-interventional study (NIS) that aims to describe the demo...
Show More Location
Hamad Medical Corporation
Learn More & Join Trial
Study of PF-07248144 in Advanced or Metastatic Solid Tumors PHASE2 This is an open-label, multi center study to evaluate safety, tolerability,...
Show More Learn More & Join Trial
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression PHASE2 Analysis of circulating tumour DNA (ctDNA) found in a patient's peripheral ...
Show More Status
Active Not Recruiting
Location
Addenbrookes Hospital
Learn More & Join Trial
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer N/A This is a multi-center, observational study designed to explore the regulat...
Show More Location
Cancer Hospital, ChineseAMS
Learn More & Join Trial
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) PHASE3 A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inh...
Show More Status
Active Not Recruiting
Learn More & Join Trial
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer PHASE3 POLAR is a phase III clinical trial, which will test the safety and efficac...
Show More Status
Active Not Recruiting
Location
Medizinische Universität Graz (MUG)
Learn More & Join Trial